12 Most Profitable Pharmaceutical Stocks Right Now

Page 9 of 9

1. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Net Income Growth 5Y: 78.87% 

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a prominent neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company is known for its innovative approach to addressing complex diseases that often have limited treatment options. The corporation’s product portfolio includes FDA-approved therapies for conditions such as tardive dyskinesia, Huntington’s disease chorea, endometriosis, and uterine fibroids, developed in collaboration with AbbVie.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported strong financial results in Q3 2024, with INGREZZA delivering $613 million in sales, marking a 25% year-over-year growth. This growth is attributed to increased patient demand and expanded market reach for treating Tardive Dyskinesia and Huntington’s Disease Chorea. Despite missing earnings expectations with an EPS of $1.24 against the expected $1.51, the company has maintained a positive outlook due to its strategic investments and pipeline development. The company’s focus on high-value pipeline assets and strategic capital allocation supports its long-term profitability.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has announced a $300 million share repurchase plan, indicating confidence in its undervalued stock and commitment to returning capital to shareholders.

As of Q3 2024, 49 hedge funds included the company in their portfolios, according to data from the Insider Monkey database. Analysts on Wall Street have given the stock a consensus rating of “Strong Buy,” with a 12-month average price target of $166.53. Price projections range from $121.00 to $192.00, suggesting a potential upside of 31.01% from its current trading price of $127.11.

Overall, NBIX  ranks first among the 12 most profitable pharmaceutical stocks right now. While we acknowledge the potential of pharmaceutical companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NBIX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9